Jason Ryan

Jason has served in executive leadership roles across diagnostics and therapeutics companies, with broad experience in scaling businesses from early stage to product launch and ultimately global commercialization.

Jason served as COO and CFO of Magenta Therapeutics (Nasdaq: MGTA), a company focused on developing cutting-edge therapeutics for patients with autoimmune diseases and blood cancers. Prior to that, Jason served as the CFO of Foundation Medicine, a transformative company in oncology molecular profiling. He helped lead that business through early development, its initial public offering, subsequent growth into a global commercial organization and ultimately its acquisition by Roche Holdings (Nasdaq: RHHBY). Prior to Foundation Medicine, Jason led the finance and strategic planning efforts of several other high growth life science companies.

Jason previously served on the board of directors of ArcherDX, Inc. (acquired by Invitae Corporation (NYSE: NVTA)). He began his career at Deloitte & Touche where he earned a CPA, and he received a BA in Economics from Bates College and an MBA from Babson College.